Genmab
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
CEOJan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees2,682
Employees2,682
HeadquartersCopenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded1998
Founded1998
Employees2,682
Employees2,682
GMAB Key Statistics
Market cap20.76B
Market cap20.76B
Price-Earnings ratio13.64
Price-Earnings ratio13.64
Dividend yield—
Dividend yield—
Average volume1.64M
Average volume1.64M
High today$32.80
High today$32.80
Low today$32.02
Low today$32.02
Open price$32.14
Open price$32.14
Volume3.24M
Volume3.24M
52 Week high$33.65
52 Week high$33.65
52 Week low$17.24
52 Week low$17.24
Stock Snapshot
The current Genmab(GMAB) stock price is $32.35, with a market capitalization of 20.76B. The stock trades at a price-to-earnings (P/E) ratio of 13.64.
On 2025-12-20, Genmab(GMAB) stock traded between a low of $32.02 and a high of $32.80. Shares are currently priced at $32.35, which is +1.0% above the low and -1.4% below the high.
The Genmab(GMAB)'s current trading volume is 3.24M, compared to an average daily volume of 1.64M.
During the past year, Genmab(GMAB) stock moved between $17.24 at its lowest and $33.65 at its peak.
During the past year, Genmab(GMAB) stock moved between $17.24 at its lowest and $33.65 at its peak.
Analyst ratings
64%
of 25 ratingsBuy
64%
Hold
32%
Sell
4%